Drug Trial Radar · NCT06402331
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Actual
Start
Mar 5, 2024
Primary completion
Dec 23, 2026
Study completion Jan 23, 2031
Sponsor
- Lead sponsor
- Fusion Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- May 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
FPI-2265Drug
Investigational treatment FPI2265 is a PSMA ligand radiolabelled with 225Ac. Other Names: 225Ac-PSMA-I\&T
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency, duration, and severity of treatment-emergent adverse events (TEAEs)Time frame: From first dose until end of long-term follow-up, 5 years from end of treatment visit.
- Frequency and proportion of participants with PSA50 responseTime frame: From first dose until 12 weeks after the first administered dose of FPI-2265.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Hoag Health Center Irvine
Irvine, California
VA Greater Los Angeles Healthcare System
Los Angeles, California
University of California Los Angeles
Los Angeles, California
UCSF School of Medicine
San Francisco, California
Biogenix Molecular, LLC
Miami, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
United Theranostics
Glen Burnie, Maryland
BAMF Health
Grand Rapids, Michigan
SSM Health Saint Louis University Hospital
St Louis, Missouri
XCancer
Omaha, Nebraska
New Mexico Oncology Hematology Consultants Ltd.
Albuquerque, New Mexico
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York
Memorial Sloan Kettering Cancer Center - NYC
New York, New York
Oregon Health and Science University (OHSU, Knight Cancer Center)
Portland, Oregon
VA North Texas Health Care System, Nuclear Medicine Service
Dallas, Texas
The University of Texas Southwestern Medical Center
Dallas, Texas
U.T. MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.